Unmet UK demand for SSTR-targeted PET (2025)
Cancer diagnosis and treatment
Accessible
Accessible
nuclear medicine
for everyone
Radiopharmaceuticals for cancer, designed for reliable production and wider patient access.
The problem
Patients are waiting for scans
Short shelf-lives and limited production keep SSTR-targeted PET tracers scarce, so patients wait for essential scans.
Our answer
FETO for wider access
Made with fluorine-18 (18F), the most widely produced medical radionuclide, on single-use cassettes, to reach more hospitals more reliably.
Output per batch vs gallium-68 (68Ga)
Delivery distance vs 68Ga DOTATATE
Company estimate of UK SSTR-PET demand, 2025; production figures from pilot runs in Cambridge.
Lead programme
Phase 2 completed
NMX-001A (FETO)
FETO is an 18F PET tracer targeting somatostatin receptor 2 (SSTR2). Our initial focus is neuroendocrine tumours, with potential in other SSTR-positive cancers.
Target
Somatostatin receptor 2
Initial focus
Neuroendocrine tumours
Radionuclide
18F
Chemical name
[18F]FET-βAG-TOCA
Why it matters
Why fluorine-18 matters
Fluorine-18 (18F) offers broader distribution reach and efficient dose production compared with generator-based isotopes.
Clinical access
Scalable production designed for diverse health systems.
De-risked biology
Starting from clinically validated SSTR2 and translational evidence.
Repeatable pipeline
One approach across radionuclides and cancers.
Standardised synthesis
Automation-ready cassettes for multi-site replication.
Our platform
The chemistry behind our programmes
Click chemistry links a targeting molecule to a radioactive label, for diagnosis or therapy.
Modular design
Same targeting molecule, interchangeable label.
18F
Our lead tracer FETO: wider reach, larger batches.
211At
Astatine-211: alpha particles for potent, short-range cell killing.
161Tb
Terbium-161: Auger electrons with high relative biological effectiveness (RBE).
Partnering
Partner with us
Work with NuclearMediX
Let’s talk about studies, production and licensing.